RxDoctor Payments Data

Victoria Timmermans, MD

Family Medicine · Cleveland, GANPI 1821613811

Payments from drug & device makers

$2,227in general payments, 2019–2025

Across 99 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$511
  • AstraZeneca$344
  • Novo Nordisk$248
  • Amgen$194
  • Pfizer$167
  • AbbVie$136
  • plus $625 from 15 others

What the payments were for

  • Food & beverage$2,227100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,227 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$71,587
Medicare patients
124
Services billed
1,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide161$204,735
OzempicSemaglutide100$104,196
JardianceEmpagliflozin29$40,733
RybelsusSemaglutide22$37,277
RexultiBrexpiprazole11$26,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$25,559
TrulicityDulaglutide13$12,351
MyrbetriqMirabegron24$12,141
FarxigaDapagliflozin Propanediol18$11,138
BelsomraSuvorexant18$7,663
DayvigoLemborexant16$6,638
ShingrixVaricella-Zoster Ge/As01b/Pf24$5,361
Gabapentin126$2,968
Ondansetron OdtOndansetron106$2,447
SynthroidLevothyroxine Sodium34$2,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$511$217,086174 claims
Novo NordiskOzempic, Rybelsus$248$141,473122 claims
Boehringer IngelheimJardiance$54$40,73329 claims
GSKTrelegy Ellipta, Shingrix$35$30,92049 claims
Otsuka America Pharmaceutical, Inc.Rexulti$97$26,86611 claims
AstraZenecaFarxiga$344$11,13818 claims
AbbVieSynthroid$136$2,17834 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,071138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cleveland

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →